Gastroretentive Drug Delivery Systems: Principles & Types (Part 1) | M.Pharm

Bioavailability is the rate and extent to which a drug reaches systemic circulation, reflecting its pharmacological effect. Drug absorption is the process of unchanged drug movement from the site of administration to the bloodstream. Pharmacokinetics studies the time course of drug movement including absorption, distribution, metabolism, and excretion (ADME). The drug absorption curve plots plasma concentration over time, showing the therapeutic window between minimum effective concentration (MEC) and minimum toxic concentration (MTC). Drug absorption through the GI tract occurs through three main mechanisms: (1) Passive transport (no energy required) including passive diffusion (following Fick's First Law), pore transport, ion pair transport, and facilitated diffusion; (2) Active transport (requires ATP) including primary and secondary active transport moving drugs against concentration gradients; and (3) Vesicular transport (endocytosis) for large molecules including phagocytosis and pinocytosis.

Active transport moves substances against concentration gradients using cellular metabolic energy, used for highly hydrophilic compounds like glucose, amino acids, vitamins, and hormones. Some drugs structurally resemble natural substances and use the same carrier systems (e.g., amino-penicillins use peptide transporters, levodopa uses phenylalanine transporters). Some drugs combine multiple absorption mechanisms simultaneously. Ion pair formation allows ionized drugs to bind oppositely charged compounds, forming neutral complexes that diffuse through lipophilic membranes. An absorption window is a specific GI tract region where drug absorption occurs selectively. When transit is rapid and windows are limited, drugs may pass through before complete dissolution and absorption occur.

Ion pair transport is used by strongly ionized drugs like quaternary ammonium compounds and sulfonic acids. Ionized drugs exist as anions or cations, which bind with oppositely charged endogenous ions to form neutral ion pair complexes that are lipid-soluble and pass through the lipid membrane, then dissociate in blood stream. Carrier-mediated transport moves drugs with specific carrier proteins through reversible non-covalent binding. It is structure-specific, carrier-limited, and has an absorption window. Kinetics: first-order at low concentrations, zero-order at high concentrations due to carrier saturation. Facilitated diffusion moves drugs from high to low concentration with carrier help, without ATP, faster than simple passive diffusion but saturable. Active transport moves drugs from low to high concentration against gradient, requiring ATP. Primary active transport includes ion pair transport and ABC transporters (like P-glycoprotein causing multidrug resistance in cancer cells). Secondary active transport uses indirect energy from ion concentration gradients, including symport (same direction) and antiport (opposite direction). Endocytosis is the only mechanism for water-insoluble substances and macromolecules, involving vesicle formation through membrane engulfment. Types: phagocytosis (solids) and pinocytosis (fluids).

Biopharmaceutics bridges pharmacology and pharmaceutical sciences, studying how drug properties affect biological effects. The science encompasses formulation, technology, and industrial applications. Key concepts include bioavailability (extent and rate of drug reaching site of action) and drug distribution (movement between plasma and extravascular fluids). Drug absorption depends on physical and chemical properties, with non-ionized forms absorbing faster due to lipophilicity. Excipients can improve solubility or control release. Enteric coating protects acid-sensitive drugs by dissolving only in basic intestinal environments.

For oral drug delivery, the absorption window in the gastrointestinal tract is approximately 8-12 hours, primarily in the small intestine. Drugs must be released within this window to be absorbed effectively. The absorption half-life is approximately 3-4 hours, meaning half the drug is absorbed within this time. For successful sustained release, the release rate constant should be less than the absorption rate constant (approximately 0.2-0.3 h⁻¹) to ensure the drug is absorbed before passing through the absorption window.

Controlled drug delivery systems address the limitations of conventional dosage forms by releasing drugs at predetermined rates, specific intervals, and with specific release profiles. These systems are preferred over developing entirely new drugs due to the significant time and cost involved in drug development. The three main modes of drug delivery are targeted delivery, controlled release, and modified release. Controlled release systems operate on advanced engineering principles with control approaches and may include logic elements with or without sensors. The fundamental basis for these systems is diffusion theory, which describes how molecules transfer spontaneously to equalize chemical potential. Fick's First Law states that particle movement is directly proportional to the concentration gradient (J = -D × DC/DX), applying to steady-state conditions. Fick's Second Law addresses non-steady state diffusion, describing how concentration changes over time depend on the second derivative of the concentration gradient (DC/DT = B × D²C/DX²).

Controlled drug delivery systems release drugs at predetermined rates over extended periods, including sustained release systems (like OROS osmotic pumps) and controlled release systems (microencapsulated and hydrogel-based). Targeted drug delivery systems deliver drugs specifically to target cells or tissues through passive targeting (EPR effect in tumors), active targeting (ligand-antibody conjugates), or physical targeting (magnetic fields). Examples include monoclonal antibody-drug conjugates and doxorubicin-loaded nanoparticles for cancer therapy.

Traditional drug delivery (pills, injections) creates dangerous peak-valley concentration patterns where drugs spike then drop below therapeutic levels, causing toxicity or ineffectiveness. Sustained release systems, developed over 100 years ago, extended release duration using coatings, resins, and suspensions but remained limited to hours and were environmentally sensitive. Controlled release formulations, emerging over 40 years ago, use polymers and pumps to deliver drugs for days to years with predictable, environment-independent release. Targeted delivery represents the next frontier, using liposomes, microspheres, and antibody-drug conjugates to direct drugs to specific body locations.

Controlled release drug delivery systems deliver drugs in predetermined amounts at predetermined rates to ensure safety and improve efficacy through constant plasma drug levels and reduced dosing frequency. These systems address conventional dosage form limitations including rapid release, poor absorption control, high dosing frequency, poor patient compliance, fluctuating blood levels, poor bioavailability, and premature metabolism. The technology encompasses sustained release systems (slow continuous release using matrix/coating mechanisms) and controlled release systems (predetermined rates via diffusion, dissolution, osmotic pressure, pH/temperature changes, enabling pulsatile, zero-order, or targeted release). Key design parameters include elimination half-life (2-6 hours), molecular weight (<150 for spherical, <400 for chain-like), absorption rate exceeding release rate, solubility ≥0.1-1%, bioavailability ≥75%, therapeutic window breadth, and low protein binding. Drugs unsuitable include those with narrow therapeutic index, large doses, extreme half-lives, low solubility, or extensive first-pass metabolism.

Controlled drug delivery systems employ fundamental mechanisms including dissolution (drug dissolving from polymer matrix), diffusion (molecules moving through polymer network), and erosion (polymer breakdown). Water penetration controls release rates, with rates inversely proportional to polymer molecular weight. Hydrophilic polymer matrices swell upon hydration, creating channels for drug diffusion. Erosion-controlled systems release drugs from degrading surfaces. Osmotic pumps use semi-permeable membranes and osmotic pressure for precise, time-controlled release. Ion exchange systems utilize reversible binding to charged polymer sites, enabling release triggered by pH changes or counterion concentrations. These mechanisms can be combined or optimized to achieve desired release profiles for therapeutic applications.

The ideal characteristics of polymers for MDDS include: (1) Polymer hydration and mucus cohesive properties that promote mucoadhesion; (2) Swelling that favors polymer chain flexibility and interpenetration between polymer and mucin chains; (3) Highly cross-linked polymers that swell in the presence of water while retaining their structure; (4) Optimum mucoadhesion at low pH conditions; (5) High viscosity and spatial confirmation; (6) Polymer flexibility that promotes interpenetration within the mucus network; (7) Chain length that must be long enough to promote interpenetration but not too long as it creates diffusion problems.

Mucoadhesive polymers are biomaterials that can bind to biological surfaces such as cells, tissues, or organs where mucus is present, functioning as 'biological glues' to stick to the site of administration; these polymers require hydrophilic functional groups (O, CO, NH2) for hydrogen bonding, water uptake capability for wet adhesion, and strong adhesion when dried, with adhesion strength depending on hydration level, polymer flexibility, and interaction with mucin; ideal characteristics include biocompatibility (non-toxic, non-immunogenic), site-specific targeting, stability under various conditions, compatibility with other formulation ingredients, proper hydration balance, flexible chains for interlinking with mucin, swelling and retention properties, pH/temperature sensitivity, and cost-effectiveness; classification is based on sources (synthetic polymers like cellulose derivatives, acrylicates, polyvinyl compounds; natural polymers like chitosan, gelatin, hyaluronic acid, pectin, sodium alginate), water solubility (soluble vs insoluble), charge (cationic, anionic, nonionic), and adhesion mechanism (covalent bonds, hydrogen bonds/electrostatic interactions, physical entanglement); the mechanism of mucoadhesion involves two stages: contact stage (spreading, swelling, and initiating deep contact with mucus) and consolidation stage (dehydration and diffusion, where water moves into the formulation and chains interpenetrate with mucin glycoproteins).

Mucoadhesion occurs through three primary mechanisms: (1) Diffusion theory - the polymer swells upon contact with gastric fluids and diffuses into the mucus layer; (2) Physical mechanical bonding - the polymer physically interpenetrates the mucus network; (3) Chemical bonding - covalent or hydrogen bonds form between polymer functional groups and mucus proteins. Effective mucoadhesive polymers contain hydrophilic functional groups like hydroxyl (-OH) groups that can form hydrogen bonds with mucus proteins, enhancing adhesion strength and retention time.

Mucoadhesion operates through four theoretical frameworks: wetting theory (polymer spreading and intimate contact), diffusion theory (physical entanglement between mucus and polymer chains), absorption theory (hydrogen bonding forces), and electronic theory (electrostatic attraction between glycoproteins and polymer). The adhesion mechanism involves two stages: contact stage (spreading and swelling upon mucosal contact) and consolidation stage (moisture-induced fragmentation and cross-linking through weak bonds). Drug transport occurs via transcellular (through cells) or paracellular (between cells) pathways. For systemic circulation, drugs must overcome enzymatic barriers on the mucosal surface. These mechanisms collectively determine drug release rates and therapeutic effectiveness in mucosal drug delivery systems.

Mucoadhesion occurs through specific molecular interactions between mucoadhesive polymers and mucus membranes. Several theories explain this phenomenon: (1) Electronic theory - opposite electrical charges attract, with negatively charged mucus membranes binding to positively charged polymers; (2) Adsorption theory - weak intermolecular forces (Van der Waals forces) create bonds between polymer and mucus surfaces; (3) Dehydration theory - water molecules are removed from the interface, strengthening adhesion; (4) Diffusion theory - polymer chains interpenetrate with mucus chains; (5) Fracture theory - polymer chains physically entangle with mucus fibers.